WT1 (WT1 transcription factor; HGNC:12796, NCBI Gene 7490) is the gene on chromosome 11p13 encoding WT1 — the zinc-finger transcription factor (and RNA-binding protein) that directs kidney and gonadal development: mesenchyme-to-epithelium conversion, ureteric-bud interactions, and the mesothelium's growth control. Its loss drives Wilms tumor (the childhood kidney cancer named for it), and its gain-of-function germline variants cause Denys-Drash and Frasier syndromes — the same gene, dominant-negative versus splice-shifted, giving two distinct renal-development diseases. WT1's isoform biology (±KTS) even assigns the splice variants separate roles — transcription factor versus RNA-binding.
WT1 → podocyte and nephrogenic genes; mesenchymal-epithelial transition control
Clinical / Therapeutic Role
Wilms-tumor suppressor; Denys-Drash/Frasier syndromes; AML prognostics
Gene Structure & Expression
Genomic organization: Ten exons with two splice sites generating the ±KTS isoform pair (the KTS insert shifting DNA-binding to RNA-processing roles) and the ±17aa variants — the isoform balance Frasier syndrome's splice mutation disrupts.
Expression: Developing kidney (metanephric blastema, podocytes lifelong), gonads, and mesothelium — the WAGR syndrome's WT1-plus-PAX6 contiguous deletion mapping the gene's neighbors, see PAX6.
Molecular Function & Pathways
Developmental roles: WT1's dual transcriptional and post-transcriptional action (the KTS isoforms binding RNA) directing the kidney's mesenchymal-to-epithelial transitions and podocyte slit-diaphragm gene expression (NPHS1/nephrin among targets).
Tumor suppression: WT1 loss (with 11p13/11p15 LOH) releasing the blastema's proliferation — Wilms tumor's genetics; WT1 mutated in ~10–20% of Wilms and deleted in WAGR.
Clinical & Therapeutic Significance
Clinical genetics: Denys-Drash (dominant-negative WT1, nephropathy + genital anomalies + Wilms risk) and Frasier (splice-site, focal segmental glomerulosclerosis + gonadoblastoma risk) — the two WT1 syndromes; WAGR's contiguous-gene diagnosis.
Oncology: WT1 overexpression (not loss) in AML and mesothelioma — the WT1-peptide vaccine programs' basis; minimal-residual-disease monitoring by WT1 transcripts.